You can buy or sell MGEN and other stocks, options, ETFs, and crypto commission-free!
Miragen Therapeutics, Inc. Common Stock, also called Miragen Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Read More Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Miragen Therapeutics
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels i...
Guru FocusMar 14
Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018
Miragen Therapeutics Inc (NASDAQ:MGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics.
Simply Wall StMar 13
What Kind Of Shareholder Owns Most Miragen Therapeutics, Inc. (NASDAQ:MGEN) Stock?
A look at the shareholders of Miragen Therapeutics, Inc. (NASDAQ:MGEN) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership. With a market capitalization of US$79m, Miragen Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of th...
-$0.31 per share
-$0.33 per share